Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 3/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323641 | 0.91 | FLT3 (0.58) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B | |
| SCHEMBL10322579 | 0.90 | FLT3 (0.61) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B | |
| SCHEMBL10323703 | 0.89 | CCNT1 (0.49) | EIF2AK2CXCR4DYRK1ADYRK1BFLT3 | |
| SCHEMBL10323345 | 0.87 | FLT3 (0.59) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B | |
| SCHEMBL10324576 | 0.86 | MKNK1 (0.49) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B | |
| SCHEMBL10322219 | 0.84 | LMNA (0.47) | EIF2AK2CXCR4FLT3BACE1LMNA | |
| SCHEMBL10322500 | 0.82 | MKNK1 (0.50) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B | |
| SCHEMBL10322415 | 0.82 | FLT3 (0.51) | EIF2AK2MKNK1DYRK1ADYRK1BFLT3 | |
| SCHEMBL10321912 | 0.81 | MKNK1 (0.49) | EIF2AK2MKNK1DYRK1ADYRK1BFLT3 | |
| SCHEMBL10321917 | 0.81 | DYRK1A (0.64) | EIF2AK2CXCR4MKNK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | claimed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | TYMS, TYMP, TP53 | EIF2AK2 1860/4885CXCR4 1691/4885MKNK1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.